BGXX

Bright Green Corporation Common Stock

BGXX

Market cap $28.3M

Overview Fund Activity

Delisted

BGXX was delisted on the 18th of September, 2024.

Back to rankings

About: Bright Green Corp is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured for research and pharmaceutical applications, as well as being an active ingredient in consumer-based solutions. The company plans to focus on the development of cannabis strains and sales of products with high contents of CBN (cannabinol) and CBG (cannabigerol).

Employees: 5

Healthcare Drug Manufacturers - Specialty & Generic

Financial journalist opinion

Bloomberg Markets and Finance

Wedbush's Ives Sees 'Bright Green Light' for Tech Stocks

Dan Ives, Wedbush Securities managing director and global head of technology research, says the Federal Reserve's rate cut cycle will "turbocharge" the rally in tech stocks. Speaking with Romaine Bostick on "Bloomberg The Close," Ives says tech stocks could be up another 10% between now and the end of the year.

Wedbush's Ives Sees 'Bright Green Light' for Tech Stocks

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A

Fort Lauderdale, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers. This segment, while modest in size compared to the broader pharmaceutical industry, represents a critical opportunity to restore control, compliance, and domestic production with a fair transparent pricing model.

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A

Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman

Tesla Robotics to Power Sovereign “Seed to Syringe” Pharmaceutical Infrastructure Fort Lauderdale, FL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty.

Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman

Bright Green Corporation Announces the next steps for the completion of its restructuring plan

FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the “RSA” Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution.

Bright Green Corporation Announces the next steps for the completion of its restructuring plan

Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the “RSA” Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution.

Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

The Company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain.

Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.

GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced today that Lynn Stockwell has agreed to terms for a restructuring security agreement (“RSA”) with Bright Green that is expected to be executed soon.Lynn Stockwell, the founder of Bright Green Corporation, Drugs Made in America Acquisition Corp I, and Drugs Made in America Acquisition Corp II seeks to align her vision to on-shore the end-to-end active pharmaceutical ingredient (“API”) manufacturing back to the United States. The plan realigns the Company with her plan to scale and position the Company as the facilitator and supplier of plant-based controlled substances authorized to manufacture in the United States. The restructuring and new direction will include the cancellations of all the company's existing contracts expressed or implied, land purchase options, employment agreements, board member agreements, financing agreements, and warrants.

LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.

Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships

GRANTS, NEW MEXICO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”), today announced that trading of its shares have been suspended from the Nasdaq Stock Exchange (“Nasdaq”) after Nasdaq cancelled the scheduled September 26, 2024 delist appeal hearing. While this development represents a change in the Company's public trading status, Bright Green remains committed to pursuing its strategic goals and delivering value to its shareholders.

Bright Green Corporation Provides an Update, Reinforces Commitment to Shareholders, and Focuses on Growth and Strategic Partnerships

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.

BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.

See News Rankings

Charts implemented using Lightweight Charts™